Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

68 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Preclinical evaluation of invariant natural killer T cells in the 5T33 multiple myeloma model.
Nur H, Fostier K, Aspeslagh S, Renmans W, Bertrand E, Leleu X, Favreau M, Breckpot K, Schots R, De Waele M, Van Valckenborgh E, De Bruyne E, Facon T, Elewaut D, Vanderkerken K, Menu E. Nur H, et al. Among authors: van valckenborgh e. PLoS One. 2013 May 31;8(5):e65075. doi: 10.1371/journal.pone.0065075. Print 2013. PLoS One. 2013. PMID: 23741460 Free PMC article.
Epigenetic silencing of the tetraspanin CD9 during disease progression in multiple myeloma cells and correlation with survival.
De Bruyne E, Bos TJ, Asosingh K, Vande Broek I, Menu E, Van Valckenborgh E, Atadja P, Coiteux V, Leleu X, Thielemans K, Van Camp B, Vanderkerken K, Van Riet I. De Bruyne E, et al. Among authors: van valckenborgh e, van camp b, van riet i. Clin Cancer Res. 2008 May 15;14(10):2918-26. doi: 10.1158/1078-0432.CCR-07-4489. Clin Cancer Res. 2008. PMID: 18483358
Stimulation of invariant natural killer T cells by α-Galactosylceramide activates the JAK-STAT pathway in endothelial cells and reduces angiogenesis in the 5T33 multiple myeloma model.
Nur H, Rao L, Frassanito MA, De Raeve H, Ribatti D, Mfopou JK, Van Valckenborgh E, De Bruyne E, Vacca A, Vanderkerken K, Menu E. Nur H, et al. Among authors: van valckenborgh e. Br J Haematol. 2014 Dec;167(5):651-63. doi: 10.1111/bjh.13092. Epub 2014 Aug 21. Br J Haematol. 2014. PMID: 25142285 Free article.
Tumour-associated macrophage-mediated survival of myeloma cells through STAT3 activation.
De Beule N, De Veirman K, Maes K, De Bruyne E, Menu E, Breckpot K, De Raeve H, Van Rampelbergh R, Van Ginderachter JA, Schots R, Van Valckenborgh E, Vanderkerken K. De Beule N, et al. Among authors: van rampelbergh r, van ginderachter ja, van valckenborgh e. J Pathol. 2017 Mar;241(4):534-546. doi: 10.1002/path.4860. Epub 2017 Jan 30. J Pathol. 2017. PMID: 27976373
Multifunctional role of matrix metalloproteinases in multiple myeloma: a study in the 5T2MM mouse model.
Van Valckenborgh E, Croucher PI, De Raeve H, Carron C, De Leenheer E, Blacher S, Devy L, Noël A, De Bruyne E, Asosingh K, Van Riet I, Van Camp B, Vanderkerken K. Van Valckenborgh E, et al. Among authors: van camp b, van riet i. Am J Pathol. 2004 Sep;165(3):869-78. doi: 10.1016/S0002-9440(10)63349-4. Am J Pathol. 2004. PMID: 15331411 Free PMC article.
Targeting the IGF-1R using picropodophyllin in the therapeutical 5T2MM mouse model of multiple myeloma: beneficial effects on tumor growth, angiogenesis, bone disease and survival.
Menu E, Jernberg-Wiklund H, De Raeve H, De Leenheer E, Coulton L, Gallagher O, Van Valckenborgh E, Larsson O, Axelson M, Nilsson K, Van Camp B, Croucher P, Vanderkerken K. Menu E, et al. Among authors: van valckenborgh e, van camp b. Int J Cancer. 2007 Oct 15;121(8):1857-61. doi: 10.1002/ijc.22845. Int J Cancer. 2007. PMID: 17546599
68 results